Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
April 26 2022 - 4:06PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF THE
SECURITIES EXCHANGE ACT OF 1934
For the month of April 2022
Commission File Number 001-37652
Midatech Pharma PLC
(Translation of registrant’s name into
English)
1 Caspian Point,
Caspian Way,
Cardiff, CF10 4DQ, United Kingdom
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will
file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the
Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the
Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
This Report on Form 6-K, including Exhibit 99.1,
is hereby incorporated by reference into the Company’s Registration Statements on Form F-3 (File No. 333-233901).
SUBMITTED HEREWITH
Attached to the Registrant’s Form 6-K filing for the month of
April 2022, and incorporated by reference herein, is:
Exhibit No. |
|
Description |
|
|
99.1 |
|
Press release, dated April 26, 2022 entitled
“Preliminary Results for the Year Ended
31 December 2021” |
The information in the attached Exhibit 99.1 is being furnished
and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the
“Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference
in any filing made by the Registrant under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise set forth
herein or as shall be expressly set forth by specific reference in such a filing.
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
Midatech Pharma PLC |
|
|
|
|
Date: April 26, 2022 |
|
|
|
By: |
|
/s/ Stephen Stamp |
|
|
|
|
|
|
|
|
Stephen Stamp
Chief Executive Officer, Chief Financial Officer |
Exhibit Index
Exhibit No. |
|
Description |
|
|
99.1 |
|
Press release, dated April 26, 2022 entitled
“Preliminary Results for the Year Ended
31 December 2021” |
Midatech Pharma (NASDAQ:MTP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Midatech Pharma (NASDAQ:MTP)
Historical Stock Chart
From Sep 2023 to Sep 2024